Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 6,129

Document Document Title
WO2004005478A3
This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA cons...  
WO2003082777A3
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as glucocorticoid receptor modulators. The compounds of the instant invention are ligands for glucocorticoid receptors and as such may be ...  
WO/2004/026815A2
The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -...  
WO2003075853A3
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restinosis, organ tra...  
WO2003102044A3
Low-cure powder coating compositions are disclosed. The compositions comprise a polyepoxide and a material having the structure: formula (I) wherein R1 is an organic radical having 6 to 25 carbon atoms; R2 is an organic radical having 1 ...  
WO/2004/022528A2
The present invention relates to compounds of Formula (I), and salts solvates and hydrates thereof. The invention further relates to pharmaceutical compositions containing said compounds and methods of treating neurological, neuropsychia...  
WO2003018535A3
The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compo...  
WO/2004/022530A1
The invention provides a compound containing a head group based on urea, glycerol or glycerate and a tail selected from the group consisting of a branched alkyl chain, a branched alkyloxy chain or an alkenyl chain. The compounds may be u...  
WO2004007459A3
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatme...  
WO/2004/022529A2
The present invention relates to novel diarylurea derivatives represented by general formula (I) useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as f...  
WO2003097587A3
The invention relates to a novel class of gelling agents, to a process of preparing said agents, to the use of said agents to prepare gels, and to the gels thus obtained. A gelling agent or thickener according to the invention comprises ...  
WO2003002524A3
The present invention relates to compounds of the formula I, in which R<1>, R<2>, R<4>, R<5>, D1, D2, X1, X2, X3, A and B have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active com...  
WO2003089615A3
Methods for evaluating the antiviral activity of test compounds are provided. Further aspects of the methods involve the retroviral capsid protein of HIV-1. In another aspect, methods of reducing mortality associated with AIDS with a com...  
WO2003088915A3
The present invention is directed to novel phenytoin derivative compounds and the use of such compounds as sodium channel blockers. Such compositions have utility as anti-cancer agents and can be used to limit or prevent PCa growth and/o...  
WO/2004/020400A1
This invention pertains to certain enzyme (CPG2) activated self-immolative nitrogen mustard prodrugs, which are useful in enzyme prodrug therapy (EPT), such as ADEPT and GDEPT, for the treatment of proliferative conditions, such as cance...  
WO/2004/013089A1
Fluorinated urethane compounds represented by the general formula (1) can impart high water- and oil-repellency: [Rf-A1-(X1(OH))-(Y1)a-OC(=O)NH-]m I [-NHC(=O)O-Y2]n [-NHC(=O)O-((ClCH2-)X2O)b-R1]k (1) wherein I is a group derived from a p...  
WO2003075857A3
Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.  
WO/2004/009558A2
The invention encompasses ureido substituted benzoic acid compounds of structure (I), compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these...  
WO/2004/007437A1
The invention relates to urea-substituted and urethane-substituted acylureas, to physiologically compatible salts thereof and to their physiologically functional derivatives. The invention thus relates to compounds of formula (I), wherei...  
WO/2004/007459A2
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatme...  
WO/2004/007407A2
The present invention includes methods and compositions for increasing the fluorous nature of an organic compound by reacting it with at least one fluorous compound to produce a fluorous tagged organic compound. The increased fluorous na...  
WO/2004/007436A1
The invention relates to a method for producing tetra-substituted ureas by reacting the corresponding amines with phosgene in the presence of an aqueous inorganic base at a temperature ranging of from 0 to 150 °C. According to the inven...  
WO/2004/005478A2
This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA cons...  
WO/2004/002941A1
The invention concerns cosmetic or dermopharmaceutical compositions comprising tyramine derivatives and their salts. The invention also concerns the method for preparing same and use thereof for reducing pigmentation.  
WO/2004/002944A1
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.  
WO/2004/002940A1
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases.  
WO/2004/000295A1
A compound of formula (I) wherein R1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group -(CH2...  
WO/2003/105846A1
The present invention relates to compounds of formula I, wherein X, Q, W, R1, R2 and R3 are as defined in the claims, which inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. T...  
WO/2003/103651A1
The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for...  
WO/2003/104188A1
The invention relates to N-benzoylureidocinnamate derivatives of formula (I), where R1-R11 have the meanings given in the claims, the physiologically acceptable salts and method for production thereof. The compounds are suitable as anti-...  
WO2003072537A3
Compounds of formula (I), or therapeutically acceptable salts thereof, are selective protein tyrosine kinase-B (PTP1B) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of disorders using the ...  
WO/2003/101927A1
Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A...  
WO2002008174A8
Novel mono- and dihydroxy phenylethylamine derivatives useful in treating melanoma are provided having the formulae (Ia, Ib or Ic). In the above formulae, R is hydrogen or -COOR, R is hydrogen or C1-6 alkyl; R and R independently represe...  
WO2003004460A3
The present invention relates to compounds of the general formula (I), processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment ...  
WO/2003/102592A2
There is disclosed a method for selectively binding micromolecules having a lysine functionality comprising the steps of: providing a sample containing one or more species of macromolecules, each having a lysine functionality; providing ...  
WO/2003/102044A2
Low-cure powder coating compositions are disclosed. The compositions comprise a polyepoxide and a material having the structure: formula (I) wherein R1 is an organic radical having 6 to 25 carbon atoms; R2 is an organic radical having 1 ...  
WO2003034989A3
Acylated alpha -hydroxyarylbutanamines and related sulfonamides, ureas and carbamates that inhibit aspartyl protease are disclosed, as are methods of treating diseases, particularly HIV, using these compounds. The compounds have the form...  
WO/2003/099776A1
The compounds of the invention are represented by the following general structure (I) or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or i...  
WO2003057169A3
The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infect...  
WO2003014064A8
Naphthylurea and naphthylacetamide derivatives of formula (I) which have vanilloid receptor 1 (VR1) antagonistic activity are disclosed, formula (I) wherein Y represents formula (II) and formula (III) and the variables Q, X, R<6>, R<7>, ...  
WO/2003/097586A1
This invention is directed to vanilloid receptor VR1 ligands of formula (1). More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment an...  
WO/2003/097587A2
The invention relates to a novel class of gelling agents, to a process of preparing said agents, to the use of said agents to prepare gels, and to the gels thus obtained. A gelling agent or thickener according to the invention comprises ...  
WO2002057242A3
Novel antagonists of alpha4beta1 integrin and/or alpha4beta7 integrin of the general Formula (I): wherein R1, R2, R5, L1, L2, Rb, W and Z are as defined in any one of claims 1 to 13, A represents -CH- or a nitrogen atom, and p is from 0 ...  
WO/2003/097619A1
A novel class of compounds of the general formula (I), which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the...  
WO2002002506A8
The present invention is substituted amines of formula (XV) useful in treating Alzheimer's disease and other similar diseases.  
WO2003051276A3
Compounds of formula (I) or (II) wherein R ¿1? , R ¿2? , R ¿3? , R ¿4? , W, Q, G, X and Y are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared...  
WO/2003/095438A1
Compounds of the formula (I); wherein formula (II) represents a substituted group, an oxa-cycloalkyl group or a thia-cycloalkyl group, are glucokinase activators useful in the treatment of type II diabetes.  
WO/2003/095420A1
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent acti...  
WO2002002505A8
The present invention is substituted amines of formula (X) useful in treating Alzheimer's disease and other similar diseases.  
WO/2003/092670A1
Compounds of formula (I): and their salts, solvates, prodrugs, etc., wherein teh substituents have the values mentioned herein, are bombesin antagonists, which have utility in variety of therapeutic areas including male and female sexual...  

Matches 701 - 750 out of 6,129